Gelesis

Gelesis is a biotechnology company, which has developed a novel hydrogel platform technology to treat obesity and is developing therapies for other chronic diseases related to the gastrointestinal (GI) tract

Gelesis

Gelesis is a biotechnology company, which has developed a novel hydrogel platform technology to treat obesity and is developing therapies for other chronic diseases related to the gastrointestinal (GI) tract

  • Gelesis’ first product, Plenity, is FDA-approved and is expected to launch in the US in 2020
  • Plenity aids weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2
  • In clinical studies, Plenity showed a unique combination of effectiveness combined with a favourable safety profile
  • In the US, Gelesis recently entered into a partnership with Ro, a leading telehealth provider, to offer high-quality remote care
  • Additionally, Gelesis is developing its investigational candidates for type 2 diabetes and prediabetes, non-alcoholic steatohepatitis (NASH) and Chronic Idiopathic Constipation (CIC)

Key facts

  1. Sales Not Disclosed
  2. Employees c. 60
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint Europe, North America
  6. Website www.gelesis.com
  7. Investment Date December 2019
  8. Fund VIP III Cortex

Investment Facts

Gelesis

Gelesis is a biotechnology company, which has developed a novel hydrogel platform technology to treat obesity and is developing therapies for other chronic diseases related to the gastrointestinal (GI) tract

Key facts

  1. Sales Not Disclosed
  2. Employees c. 60
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint Europe, North America
  6. Website www.gelesis.com
  7. Investment Date December 2019
  8. Fund VIP III Cortex
  • Gelesis’ first product, Plenity, is FDA-approved and is expected to launch in the US in 2020
  • Plenity aids weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2
  • In clinical studies, Plenity showed a unique combination of effectiveness combined with a favourable safety profile
  • In the US, Gelesis recently entered into a partnership with Ro, a leading telehealth provider, to offer high-quality remote care
  • Additionally, Gelesis is developing its investigational candidates for type 2 diabetes and prediabetes, non-alcoholic steatohepatitis (NASH) and Chronic Idiopathic Constipation (CIC)

Back